Lundbeck Canada announced today that Health Canada has approved Trintellix (vortioxetine hydrobromide) for the treatment of major depressive disorder (MDD), a debilitating mental health illness which affects more than 1 in 10 Canadians over the age of 181 and occurs about twice as often in women than in men.

“MDD manifests itself through a wide array of emotional, physical and cognitive symptoms. Beyond the mood component, changes in appetite and psychomotor activity, difficulty concentrating and making decisions, or even suicidal behaviour, are common. These symptoms can be felt by sufferers on a daily basis, often throughout the day, and seriously impede their ability to function” says Dr. Roger McIntyre, Full Professor of Psychiatry and Pharmacology at the University of Toronto and Head of the Mood Disorders Psychopharmacology Unit at the University Health Network. “With such a diverse group of symptoms, it is important to find diversity in treatment to improve patient outcomes.

For more details, go to: http://www.lundbeck.com/upload/ca/en/files/News%20room/Trintellix%20approval%20by%20Health%20Canada.pdf